Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1990 Sep;64(3):177–181. doi: 10.1136/hrt.64.3.177

Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction.

H D White 1, D B Cross 1, B F Williams 1, R M Norris 1
PMCID: PMC1024367  PMID: 2119665

Abstract

Thrombolytic treatment for acute myocardial infarction increases the risk of subsequent reocclusion of the infarct related artery. The efficacy and safety of repeat thrombolytic treatment was assessed in 31 patients treated with streptokinase (n = 13) or tissue plasminogen activator (n = 18) a median of five days (1-716) after the first infusion. The indication for readministration was prolonged chest pain with new ST segment elevation. Efficacy was assessed by infarct artery patency at angiography at a median of eight days after readministration in 22 patients and by non-invasive criteria in 23 patients (reperfusion was deemed to be likely if serum creatine kinase was not increased or reached a peak less than 12 hours after infarction). Angiography showed patency of 70% of the infarct arteries after readministration of streptokinase and of 75% after tissue plasminogen activator. The corresponding patency rates assessed noninvasively were 73% and 75%. Reinfarction was prevented in nine (29%) patients. Allergic reactions occurred in four of eight patients who received streptokinase twice (plasmacytosis and acute reversible renal failure developed in one patient). Two patients had major bleeding and two minor bleeding, all after tissue plasminogen activator, and one of them died of cerebral haemorrhage. Repeat thrombolytic treatment results in late patency rates similar to the rates after the initial administration. Allergic reactions were common in those treated twice with streptokinase.

Full text

PDF
177

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bucknall C., Darley C., Flax J., Vincent R., Chamberlain D. Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Br Heart J. 1988 Jan;59(1):9–11. doi: 10.1136/hrt.59.1.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chan N. S., White H., Maslowski A., Cleland J. Plasmacytosis and renal failure after readministration of streptokinase for threatened myocardial reinfarction. BMJ. 1988 Sep 17;297(6650):717–718. doi: 10.1136/bmj.297.6650.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Davidson J. R., Bush R. K., Grogan E. W., Boh L. A., Graziano F. M. Immunology of a serum sickness/vasculitis reaction secondary to streptokinase used for acute myocardial infarction. Clin Exp Rheumatol. 1988 Oct-Dec;6(4):381–384. [PubMed] [Google Scholar]
  4. Eden K. V. Possible association of Guillain-Barré syndrome with thrombolytic therapy. JAMA. 1983 Apr 15;249(15):2020–2021. doi: 10.1001/jama.1983.03330390028021. [DOI] [PubMed] [Google Scholar]
  5. Jalihal S., Morris G. K. Antistreptokinase titres after intravenous streptokinase. Lancet. 1990 Jan 27;335(8683):184–185. doi: 10.1016/0140-6736(90)90276-b. [DOI] [PubMed] [Google Scholar]
  6. Leaf D. A., MacDonald I., Kliks B., Wilson R., Jones S. R. Streptokinase and the Guillain-Barré syndrome. Ann Intern Med. 1984 Apr;100(4):617–617. doi: 10.7326/0003-4819-100-4-617_2. [DOI] [PubMed] [Google Scholar]
  7. McGrath K. G., Patterson R. Anaphylactic reactivity to streptokinase. JAMA. 1984 Sep 14;252(10):1314–1317. [PubMed] [Google Scholar]
  8. Meinertz T., Kasper W., Schumacher M., Just H. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol. 1988 Sep 1;62(7):347–351. doi: 10.1016/0002-9149(88)90956-3. [DOI] [PubMed] [Google Scholar]
  9. Moran D. M., Standring R., Lavender E. A., Harris G. S. Assessment of anti-streptokinase antibody levels in human sera using a microradioimmunoassay procedure. Thromb Haemost. 1984 Dec 29;52(3):281–287. [PubMed] [Google Scholar]
  10. Schröder R., Biamino G., von Leitner E. R., Linderer T., Brüggemann T., Heitz J., Vöhringer H. F., Wegscheider K. Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation. 1983 Mar;67(3):536–548. doi: 10.1161/01.cir.67.3.536. [DOI] [PubMed] [Google Scholar]
  11. Topol E. J., Califf R. M., George B. S., Kereiakes D. J., Abbottsmith C. W., Candela R. J., Lee K. L., Pitt B., Stack R. S., O'Neill W. W. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987 Sep 3;317(10):581–588. doi: 10.1056/NEJM198709033171001. [DOI] [PubMed] [Google Scholar]
  12. White H. D., Norris R. M., Brown M. A., Takayama M., Maslowski A., Bass N. M., Ormiston J. A., Whitlock T. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 1987 Oct 1;317(14):850–855. doi: 10.1056/NEJM198710013171402. [DOI] [PubMed] [Google Scholar]
  13. Wilcox R. G., von der Lippe G., Olsson C. G., Jensen G., Skene A. M., Hampton J. R. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988 Sep 3;2(8610):525–530. doi: 10.1016/s0140-6736(88)92656-6. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES